HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
darodipine
structure given in first source
Also Known As:
PY 108-068; 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, diethyl ester
Networked:
19
relevant articles (
4
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyridines: 88
Dihydropyridines: 214
Nifedipine: 5733
darodipine: 19
Related Diseases
1.
Stable Angina
01/01/1986 - "
In a double-blind, randomised crossover study in 6 patients with chronic stable angina, we compared the acute effects of a single oral dose of placebo with 25 mg and 50 mg of PY 108-068.
"
01/01/1986 - "
The efficacy of PY 108-068 (75 and 150 mg/day), a new dihydropyridine calcium antagonist, was compared with placebo for treatment of chronic stable angina.
"
2.
Exercise-Induced Asthma (Asthma, Exercise Induced)
08/01/1986 - "
Exercise-induced asthma (expressed as maximal percent fall in the forced expiratory volume in one second from before baseline) was significantly attenuated only by 150 mg of PY 108-068 compared to placebo (24 +/- 13 vs 40 +/- 16; p less than 0.05).
"
01/01/1986 - "
Exercise-induced bronchospasm (EIB), expressed as maximal percent fall in FEV1 from preexercise baseline, was attenuated by PY 108-068 as compared with placebo (% delta FEV1 of 20 +/- 6 and 40 +/- 4, respectively; p less than 0.001).
"
08/01/1986 - "
We conclude that in these patients, there was a tendency for mild bronchodilation before exercise with both 150 mg of PY 108-068 and nifedipine, but only the 150-mg dose provided significant protection against exercise-induced asthma two hours after the drug.
"
01/01/1986 - "
Bronchodilatation and attenuation of exercise-induced bronchospasm by PY 108-068, a new calcium antagonist.
"
08/01/1986 - "
In 12 asthmatic adults with relatively severe exercise-induced asthma, we compared the effect of a new calcium antagonist, PY 108-068, in doses of 75 mg and 150 mg with nifedipine (30 mg) and placebo on resting flow rates and flow rates after exercise.
"
3.
Stroke (Strokes)
07/01/1984 - "
The efficacy of PY 108-068 in a variety of ischemic insults makes this drug a promising aid in the treatment of cerebrovascular accidents.
"
07/01/1984 - "
In a chronic stroke model (microsphere embolization in rats) PY 108-068 led to a significant reduction in mortality and in the severity of neurological symptoms, whereby the peroral efficacy of the drug could be demonstrated.
"
4.
Eosinophilia
01/01/1986 - "
Protection against EIB did not correlate with the resting bronchodilation induced by PY 108-068, but was more likely if the patient had eosinophilia.
"
5.
Arterial Occlusive Diseases (Arterial Occlusive Disease)
07/01/1984 - "
Determination of brain tissue oxygenation with pO2 microelectrodes showed that PY 108-068 improved oxygen supply in the cortex of cats subjected to epicerebral arterial occlusion.
"
Related Drugs and Biologics
1.
Calcium
2.
Nifedipine (Adalat)
3.
Oxygen (Dioxygen)
4.
1,4-dihydropyridine (dihydropyridine)
5.
Isradipine (Dynacirc)
6.
Nimodipine (Modus)
7.
Nicardipine (Dagan)
8.
Calcium Channel Blockers (Blockers, Calcium Channel)
9.
Lactic Acid (Lactate)
10.
Nisoldipine
Related Therapies and Procedures
1.
Microspheres (Microsphere)
2.
Microelectrodes